This morning diabetes data management company Glooko announced that two soon-to-be released Novo Nordisk connected insulin pens will now be connected to the former’s diasend platform. The connected pens are expected to launch in early 2019, and will include Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus.
As part of today’s announcement Glooko also revealed a new compatibility feature for the ...
Glooko announced the launch of the new version of its Glooko Web Application platform this morning. The site aims to give users more resources with a streamlined navigation tool and an assortment of diabetes analytics, charts, and graphs.
“We are truly excited to supply PWDs and clinicians with the most comprehensive set of reports and analytics on diabetes data available today,” Sam Wyndbrant,...
Digital diabetes management company Glooko and device maker Dexcom have expanded their partnership, effectively creating on-demand access to continuous glucose monitor data for both physicians and patients who use the two companies’ products.
Glooko and Dexcom began working together in June 2015, when Glooko first began integrating CGMs and insulin pumps into its platform. But for the past two...
Mountain View, California-based Glooko is collaborating with Danish pharmaceutical company Novo Nordisk to develop a digital diabetes management platform.
The non-exclusive partnership, developed and branded by both companies, will combine Glooko’s digital capabilities and Novo Nordisk’s deep knowledge of diabetes. Glooko offers a mobile, cloud-based platform for people with diabetes to track and...
Two diabetes management companies, Mountain View, California-based Glooko and Gothenburg, Sweden-based Diasend, will merge into a unified company, leveraging the global capabilities of Diasend and the user-friendly platform of Glooko.
The joint solution, which will operate under the Glooko name, will now serve 4,000 diabetes clinics in 23 countries across 15 languages. The joint platform...
Germantown, Maryland-based Senseonics' Eversense continuous glucose monitor, which promises to be less invasive and longer lasting than traditional CGMs, still isn’t FDA cleared or CE-marked. But the company, which filed for an IPO last month, is pushing ahead on a partnership to maximize the user experience of its device, and to establish a pipeline for sending its data to users’ healthcare...
